Imunon Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Imunon's earnings are forecast to decline at 19.6% per annum while its annual revenue is expected to grow at 82.9% per year. EPS is expected to grow by 36% per annum.
Wichtige Informationen
-19.6%
Wachstumsrate der Gewinne
36.0%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 37.3% |
Wachstumsrate der Einnahmen | 82.9% |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 31 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Keine Aktualisierungen
Recent updates
Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | N/A | -35 | -45 | -46 | 4 |
12/31/2025 | N/A | -27 | -37 | -34 | 4 |
12/31/2024 | N/A | -22 | -29 | -29 | 4 |
6/30/2024 | N/A | -18 | -19 | -19 | N/A |
3/31/2024 | N/A | -19 | -21 | -21 | N/A |
12/31/2023 | N/A | -20 | -19 | -19 | N/A |
9/30/2023 | 0 | -28 | -21 | -20 | N/A |
6/30/2023 | 0 | -31 | -21 | -20 | N/A |
3/31/2023 | 0 | -31 | -19 | -19 | N/A |
12/31/2022 | 1 | -36 | -23 | -23 | N/A |
9/30/2022 | 1 | -27 | -23 | -23 | N/A |
6/30/2022 | 1 | -26 | -23 | -22 | N/A |
3/31/2022 | 1 | -26 | -20 | -19 | N/A |
12/31/2021 | 1 | -21 | -17 | -16 | N/A |
9/30/2021 | 1 | -20 | -15 | -15 | N/A |
6/30/2021 | 1 | -22 | -15 | -15 | N/A |
3/31/2021 | 1 | -22 | -16 | -15 | N/A |
12/31/2020 | 1 | -21 | -16 | -16 | N/A |
9/30/2020 | 1 | -22 | -18 | -18 | N/A |
6/30/2020 | 1 | -19 | -18 | -18 | N/A |
3/31/2020 | 1 | -20 | -20 | -20 | N/A |
12/31/2019 | 1 | -17 | -21 | -20 | N/A |
9/30/2019 | 1 | -8 | -9 | -9 | N/A |
6/30/2019 | 1 | -7 | -9 | -8 | N/A |
3/31/2019 | 1 | -10 | -8 | -8 | N/A |
12/31/2018 | 1 | -12 | -7 | -7 | N/A |
9/30/2018 | 1 | -22 | -17 | -17 | N/A |
6/30/2018 | 1 | -23 | -18 | -18 | N/A |
3/31/2018 | 1 | -20 | N/A | -18 | N/A |
12/31/2017 | 1 | -21 | N/A | -17 | N/A |
9/30/2017 | 1 | -21 | N/A | -17 | N/A |
6/30/2017 | 1 | -22 | N/A | -17 | N/A |
3/31/2017 | 1 | -21 | N/A | -17 | N/A |
12/31/2016 | 1 | -22 | N/A | -18 | N/A |
9/30/2016 | 1 | -22 | N/A | -18 | N/A |
6/30/2016 | 1 | -20 | N/A | -18 | N/A |
3/31/2016 | 1 | -21 | N/A | -20 | N/A |
12/31/2015 | 1 | -22 | N/A | -21 | N/A |
9/30/2015 | 1 | -23 | N/A | -23 | N/A |
6/30/2015 | 1 | -26 | N/A | -24 | N/A |
3/31/2015 | 1 | -27 | N/A | -22 | N/A |
12/31/2014 | 1 | -25 | N/A | -21 | N/A |
9/30/2014 | 1 | -23 | N/A | -18 | N/A |
6/30/2014 | 1 | -20 | N/A | -15 | N/A |
3/31/2014 | 1 | -13 | N/A | -16 | N/A |
12/31/2013 | 1 | -13 | N/A | -10 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 0HUZ is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: 0HUZ is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: 0HUZ is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: 0HUZ is forecast to have no revenue next year.
Hohe Wachstumseinnahmen: 0HUZ is forecast to have no revenue next year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if 0HUZ's Return on Equity is forecast to be high in 3 years time